STOCK TITAN

LeonaBio: Great Point reports 5.03% passive stake

The 5.03% figure is based on 9,421,663 shares outstanding reported by LeonaBio in its Form 10-Q filed August 14, 2026.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

LeonaBio, Inc. (LONA) is the issuer in a Schedule 13G reporting that Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D. (Senior Managing Member of Great Point), and Ms. Lillian Nordahl (Managing Director of Great Point) may each be deemed beneficial owners of 474,345 shares, or 5.03% of the class.

Each is listed with shared voting and dispositive power over 474,345 shares and no sole voting or dispositive power. The reporting persons disclaim beneficial ownership of the fund shares except to the extent of their respective pecuniary interests.

Beneficially owned shares 474,345 shares Reported for each of the three reporting persons
Percentage of class 5.03% Reported for each of the three reporting persons
Shares held by Biomedical Value Fund, L.P. 313,066 shares Identified as held of record
Shares held by Biomedical Offshore Value Fund, Ltd. 161,279 shares Identified as held of record
Shares outstanding 9,421,663 shares Reported in LeonaBio's Form 10-Q filed August 14, 2026
beneficial owner technical
"may be deemed to be the beneficial owner of the BVF Shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting power technical
"Shared Voting Power 474,345.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power technical
"Shared Dispositive Power 474,345.00"
pecuniary interests technical
"except to the extent of their respective pecuniary interests"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares are reported in the LONA Schedule 13G?

Each of the three reporting persons may be deemed beneficially to own 474,345 shares, or 5.03% of the class, with shared voting and dispositive power.

Which funds are record holders of the shares reported in the LONA Schedule 13G?

Biomedical Value Fund, L.P. is identified as the record holder of 313,066 shares, and Biomedical Offshore Value Fund, Ltd. is identified as the record holder of 161,279 shares.

What share count was used to calculate the LONA Schedule 13G ownership percentage?

The percentage is based on 9,421,663 shares outstanding, as reported by LeonaBio in its Form 10-Q filed August 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





04746L203

(CUSIP Number)
10/28/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Great Point Partners, LLC
Signature:/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:Dr. Jeffrey R. Jay, M.D - Senior Managing Member
Date:11/04/2026
Dr. Jeffrey R. Jay, M.D.
Signature:/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:Dr. Jeffrey R. Jay, M.D
Date:11/04/2026
Ms. Lillian Nordahl
Signature:/s/ Ms. Lillian Nordahl
Name/Title:Ms. Lillian Nordahl
Date:11/04/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: November 4, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl

Keep reading